Viral neuraminidase

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Retrieved on: 
Tuesday, August 3, 2021
Natural sciences, Chemistry, Branches of biology, Neuraminidase inhibitors, Carbohydrate chemistry, Acetamides, Guanidines, BioCryst Pharmaceuticals, Peramivir, Neuraminidase, Viral neuraminidase, Enzyme

The options were granted in accordance with Nasdaq Listing Rule 5635(c)(4).

Key Points: 
  • The options were granted in accordance with Nasdaq Listing Rule 5635(c)(4).
  • Each stock option has a 10-year term and is subject to the terms and conditions of BioCrysts Inducement Equity Incentive Plan and a stock option agreement covering the grant.
  • BioCryst Pharmaceuticals discovers novel, oral, small-molecule medicines that treat rare diseases in which significant unmet medical needs exist and an enzyme plays a key role in the biological pathway of the disease.
  • RAPIVAB (peramivir injection), a viral neuraminidase inhibitor for the treatment of influenza, has received regulatory approval in the U.S., Canada, Australia, Japan, Taiwan and Korea.

BioCryst to Present at Upcoming Investor Conferences

Retrieved on: 
Wednesday, May 5, 2021
Neuraminidase inhibitors, Chemistry, Carbohydrate chemistry, Enzymes, Branches of biology, Acetamides, Guanidines, Peramivir, Neuraminidase, BioCryst Pharmaceuticals, XC2, Viral neuraminidase

b'RESEARCH TRIANGLE PARK, N.C., May 05, 2021 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced that the company will present at the Bank of America 2021 Healthcare Conference on Wednesday, May 12, 2021 at 12:30 p.m.

Key Points: 
  • b'RESEARCH TRIANGLE PARK, N.C., May 05, 2021 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced that the company will present at the Bank of America 2021 Healthcare Conference on Wednesday, May 12, 2021 at 12:30 p.m.
  • ET and the 2021 RBC Capital Markets Global Healthcare Conference on Wednesday, May 19, 2021 at 1:20 p.m.
  • ET.
  • RAPIVAB\xc2\xae (peramivir injection), a viral neuraminidase inhibitor for the treatment of influenza, has received regulatory approval in the U.S., Canada, Australia, Japan, Taiwan and Korea.

BioCryst to Present at 20th Annual Needham Virtual Healthcare Conference

Retrieved on: 
Wednesday, April 7, 2021
Branches of biology, Chemistry, Neuraminidase inhibitors, Natural sciences, Carbohydrate chemistry, Acetamides, Guanidines, Peramivir, BioCryst Pharmaceuticals, Neuraminidase, Viral neuraminidase, Enzyme

RESEARCH TRIANGLE PARK, N.C., April 07, 2021 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced that the company will present at the 20th Annual Needham Virtual Healthcare Conference on Wednesday, April 14, 2021 at 8:45 a.m.

Key Points: 
  • RESEARCH TRIANGLE PARK, N.C., April 07, 2021 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced that the company will present at the 20th Annual Needham Virtual Healthcare Conference on Wednesday, April 14, 2021 at 8:45 a.m.
  • BioCryst Pharmaceuticals discovers novel, oral, small-molecule medicines that treat rare diseases in which significant unmet medical needs exist and an enzyme plays a key role in the biological pathway of the disease.
  • RAPIVAB(peramivir injection), a viral neuraminidase inhibitor for the treatment of influenza, has received regulatory approval in the U.S., Canada, Australia, Japan, Taiwan and Korea.
  • For more information, please visit the companys website at www.biocryst.com .

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Retrieved on: 
Tuesday, February 2, 2021
Branches of biology, Chemistry, Natural sciences, Neuraminidase inhibitors, Carbohydrate chemistry, Acetamides, Guanidines, Peramivir, BioCryst Pharmaceuticals, Neuraminidase, Viral neuraminidase, Influenza

The options were granted in accordance with Nasdaq Listing Rule 5635(c)(4).

Key Points: 
  • The options were granted in accordance with Nasdaq Listing Rule 5635(c)(4).
  • Each stock option has a 10-year term and is subject to the terms and conditions of BioCrysts Inducement Equity Incentive Plan and a stock option agreement covering the grant.
  • BioCryst Pharmaceuticals discovers novel, oral, small-molecule medicines that treat rare diseases in which significant unmet medical needs exist and an enzyme plays a key role in the biological pathway of the disease.
  • RAPIVAB (peramivir injection), a viral neuraminidase inhibitor for the treatment of influenza, has received regulatory approval in the U.S., Canada, Australia, Japan, Taiwan and Korea.

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Retrieved on: 
Thursday, January 7, 2021
Branches of biology, Chemistry, Natural sciences, Neuraminidase inhibitors, Carbohydrate chemistry, Acetamides, Guanidines, BioCryst Pharmaceuticals, Peramivir, Neuraminidase, Viral neuraminidase, Influenza

The options were granted in accordance with Nasdaq Listing Rule 5635(c)(4).

Key Points: 
  • The options were granted in accordance with Nasdaq Listing Rule 5635(c)(4).
  • Each stock option has a 10-year term and is subject to the terms and conditions of BioCrysts Inducement Equity Incentive Plan and a stock option agreement covering the grant.
  • BioCryst Pharmaceuticals discovers novel, oral, small-molecule medicines that treat rare diseases in which significant unmet medical needs exist and an enzyme plays a key role in the biological pathway of the disease.
  • RAPIVAB (peramivir injection), a viral neuraminidase inhibitor for the treatment of influenza, has received regulatory approval in the U.S., Canada, Australia, Japan, Taiwan and Korea.

BioCryst to Present at 39th Annual J.P. Morgan Healthcare Conference

Retrieved on: 
Wednesday, January 6, 2021
Branches of biology, Neuraminidase inhibitors, Chemistry, Life sciences, Carbohydrate chemistry, BioCryst Pharmaceuticals, Acetamides, Guanidines, Peramivir, Neuraminidase, Viral neuraminidase, Influenza

RESEARCH TRIANGLE PARK, N.C., Jan. 06, 2021 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will present at the 39th Annual J.P. Morgan Healthcare Conference, which is being conducted as a virtual event, on Wednesday, January 13, 2021 at 11:40 a.m.

Key Points: 
  • RESEARCH TRIANGLE PARK, N.C., Jan. 06, 2021 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will present at the 39th Annual J.P. Morgan Healthcare Conference, which is being conducted as a virtual event, on Wednesday, January 13, 2021 at 11:40 a.m.
  • BioCryst Pharmaceuticals discovers novel, oral, small-molecule medicines that treat rare diseases in which significant unmet medical needs exist and an enzyme plays a key role in the biological pathway of the disease.
  • RAPIVAB (peramivir injection), a viral neuraminidase inhibitor for the treatment of influenza, has received regulatory approval in the U.S., Canada, Australia, Japan, Taiwan and Korea.
  • For more information, please visit the Companys website at www.biocryst.com.

BioCryst to Present at JMP Securities Hematology Summit

Retrieved on: 
Friday, December 11, 2020
Branches of biology, Neuraminidase inhibitors, Chemistry, Life sciences, Carbohydrate chemistry, BioCryst Pharmaceuticals, Acetamides, Guanidines, Peramivir, Neuraminidase, Viral neuraminidase, Small molecule

RESEARCH TRIANGLE PARK, N.C., Dec. 11, 2020 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will present at the JMP Securities Hematology Summit, which is being conducted as a virtual event, on Tuesday, December 15, 2020 at 3:30 p.m.

Key Points: 
  • RESEARCH TRIANGLE PARK, N.C., Dec. 11, 2020 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will present at the JMP Securities Hematology Summit, which is being conducted as a virtual event, on Tuesday, December 15, 2020 at 3:30 p.m.
  • BioCryst Pharmaceuticals discovers novel, oral, small-molecule medicines that treat rare diseases in which significant unmet medical needs exist and an enzyme plays a key role in the biological pathway of the disease.
  • RAPIVAB(peramivir injection), a viral neuraminidase inhibitor for the treatment of influenza, is BioCrysts first approved product and has received regulatory approval in the U.S., Canada, Australia, Japan, Taiwan and Korea.
  • For more information, please visit the Companys website at www.biocryst.com .

Kanazawa University research: Real-time observation of structural dynamic of influenza A hemagglutinin during viral entry

Retrieved on: 
Friday, August 7, 2020
Proteins, Medical specialties, Branches of biology, Influenza A virus, Viral structural proteins, Hemagglutinin, Protein families, Orthomyxoviridae, Influenza, Viral neuraminidase, Influenza C virus

The devastating respiratory virus, influenza A virus, utilize its hemagglutinin (HA) proteins to search for suitable host cells.

Key Points: 
  • The devastating respiratory virus, influenza A virus, utilize its hemagglutinin (HA) proteins to search for suitable host cells.
  • More strikingly, HA undergoes structural change to mediate viral membrane to fuse with host endosomal membrane to form a hole in order to release viral components.
  • Influenza A hemagglutinin (HA) is a protein residing on the surface of influenza A virus (the culprit that causes 'the flu' or influenza), playing a key role in viral infectivity.
  • High-speed AFM reveals molecular dynamic of human influenza A hemagglutinin and its interaction with exosomes, Nano Letters Published online on July 27, 2020.

Kanazawa University research: Real-time observation of structural dynamic of influenza A hemagglutinin during viral entry

Retrieved on: 
Friday, August 7, 2020
Proteins, Medical specialties, Branches of biology, Influenza A virus, Viral structural proteins, Hemagglutinin, Protein families, Orthomyxoviridae, Influenza, Viral neuraminidase, Influenza C virus

The devastating respiratory virus, influenza A virus, utilize its hemagglutinin (HA) proteins to search for suitable host cells.

Key Points: 
  • The devastating respiratory virus, influenza A virus, utilize its hemagglutinin (HA) proteins to search for suitable host cells.
  • More strikingly, HA undergoes structural change to mediate viral membrane to fuse with host endosomal membrane to form a hole in order to release viral components.
  • Influenza A hemagglutinin (HA) is a protein residing on the surface of influenza A virus (the culprit that causes 'the flu' or influenza), playing a key role in viral infectivity.
  • High-speed AFM reveals molecular dynamic of human influenza A hemagglutinin and its interaction with exosomes, Nano Letters Published online on July 27, 2020.